InterMune to net $228m in stock, note sale to pay down debt and finance Esbriet
This article was originally published in Scrip
InterMune will pay down debt and finance its pursuit of US FDA approval for Esbriet (pirfenidone) in the treatment of idiopathic pulmonary fibrosis (IPF) with $228.1 million in aggregate net proceeds from an offering of 13.5 million shares of common stock and the concurrent sale of 2.5% convertible senior notes worth $105 million in principal.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.